Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Belen Ybarrondo"'
Autor:
Sharat Singh, Xinjun Liu, Shi Chung Ng, Robert Barham, Tani Lee, Richard Kirkland, Belen Ybarrondo, Anne Kuller, Limin Liu, Glen Leesman, Phillip Kim
Publikováno v:
Proteome Science, Vol 9, Iss 1, p 75 (2011)
Proteome Science
Proteome Science
Background The clinical benefits associated with targeted oncology agents are generally limited to subsets of patients. Even with favorable biomarker profiles, many patients do not respond or acquire resistance. Existing technologies are ineffective
Publikováno v:
Seminars in Immunology. 5:263-270
Activation of T cells involves both the antigen-specific T cell receptor and a number of additional accessory receptors. For cytotoxic T lymphocytes these include CD8, LFA-1 and VLA receptors. Recent studies have demonstrated that these receptors bec
Autor:
Belen Ybarrondo, Richard Kirkland, Anne Kuller, M. Hanna, Xinjun Liu, Tani Lee, Phillip Kim, Sharat Singh, L. Ohrmund, F. Lin
Publikováno v:
Journal of Clinical Oncology. 28:1099-1099
1099 Background: De novo and acquired resistance to trastuzumab-based therapy is an active area of research. One of the mechanisms of resistance is expression of p95HER2 which is clinically associa...
Autor:
Glen Leesman, Linda Ohrmund, Anne Kuller, Limin Liu, Richard Kirkland, Tani Lee, Robert Barham, Sharat Singh, Frederick Lin, Xinjun Liu, K. Magonova, Phillip Kim, Belen Ybarrondo
Publikováno v:
Cancer Research. 70:3179-3179
The COllaborative Proximity ImmunoAssay (COPIA) is a multiplexed protein microarray platform that utilizes the formation of a unique immuno-complex requiring co-localization of two detector-antibodies. The detector-antibodies are conjugated with corr
Autor:
Jae Moon Bae, G. Harvie, Belen Ybarrondo, Phillip Kim, Jeeyun Lee, Kyoung-Mee Kim, Jae Hyoung Noh, Won Ki Kang, Limin Liu, Xinjun Liu, Sharat Singh, Tae Sung Sohn, Joon Oh Park, Sung Kim, Tani Lee
Publikováno v:
Cancer Research. 70:4019-4019
Although gastrectomy is the only curative treatment in gastric cancer (GCA) patients, a high recurrence rate ranging from 40 ∼ 60% following curative surgery still accounts for poor overall survival. In order to further improve survival, there is a
Autor:
Sharat Singh, Belen Ybarrondo, Tani Lee, P. Kim, Xinjun Liu, F. Lin, L. Zhang, Richard Kirkland, K. Magonova, Limin Liu
Publikováno v:
Cancer Research. 69:3053-3053
Background: HER2-overexpressing breast cancer has poor prognosis and is often resistant to HER2 targeted monoclonal antibody therapy. One of the mechanisms of de novo or acquired resistance is expression of p95HER2, various forms of truncated HER2 re
Autor:
Robert Barham, Tani Lee, S. Mai, Xinjun Liu, Limin Liu, Sharat Singh, Belen Ybarrondo, G. Harvie, P. Kim
Publikováno v:
Cancer Research. 69:3010-3010
Background: HER2 is one of four trans-membrane RTKs in epidermal growth factor receptor family, and HER2-positive phenotype has been associated with aggressive subtype of breast cancer with HER2 gene amplification. Approximately 15-20% of breast canc
Autor:
K. Magonova, L. Zhang, G. Harvie, Richard Kirkland, Limin Liu, Phillip Kim, Xinjun Liu, Sharat Singh, Belen Ybarrondo
Publikováno v:
Journal of Clinical Oncology. 27:e22095-e22095
e22095 Background: The changes in the tumor receptor expression status between primary site and metastatic lesions are known to occur at a significant frequency (∼15–20%). Methods for profiling RTK activation patterns on metastatic tumors may pro
Autor:
Belen Ybarrondo, Robert Barham, Phillip Kim, Sharat Singh, J. Harvey, Tani Lee, Xinjun Liu, Limin Liu, F. Lin
Publikováno v:
Journal of Clinical Oncology. 27:11024-11024
11024 Background: The abnormal activation of HER1 and HER2 has been linked to various types of cancer progression, and the changes in their expression status between primary tumor and CTCs have been reported to occur at a significant frequency. Metho
Publikováno v:
Cancer immunology, immunotherapy : CII. 31(4)
We recently reported that interleukin-2(IL-2)-activated peripheral blood lymphocytes and CD3+, lymphokine-activated killer (LAK) cell clones release tumor necrosis factor alpha(TNF alpha) and interferon gamma (IFN gamma) when stimulated with K562 ery